HER2 Status in Esophagogastric Adenocarcinoma and Its Associations With Patient's Clinicopathological Outcomes

Launched by ST. JAMES'S HOSPITAL, IRELAND · Aug 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how a specific protein called HER2 affects patients with esophagogastric adenocarcinoma, which is a type of cancer that can occur in the esophagus or stomach. Researchers want to understand how common HER2 overexpression is in these patients and how it relates to their treatment outcomes. The study also aims to explore if there are differences in HER2 levels within the tumors and between different patients, which could help tailor future treatments.

To participate in this study, you need to be at least 18 years old and have a newly diagnosed case of esophagogastric adenocarcinoma after the year 2000. Your HER2 status must have been tested as part of your routine care. Unfortunately, if you have a different type of esophageal cancer called squamous cell carcinoma, you won’t be eligible for this trial. If you join, you'll be contributing to important research that could improve treatment options for future patients with this type of cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with newly diagnosed EGA from 2000 to April 2024 across all stages of disease
• • Primary tumour HER2 status tested as routine in all patients with EGA
• • Patients aged 18 years or over
• Exclusion Criteria:
• • - Patients with esophageal squamous cell carcinoma